Logo of Swiss drugmaker Roche is seen beside the entrance of its research unit Roche Glycart AG in Schlieren, Switzerland December 18, 2017. REUTERS/Arnd Wiegmann
(Reuters) – Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer.
The Tecentriq regimen showed significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer, the drugmaker said.
The agency’s approval comes a day after the drug won priority review from the U.S. regulator.
Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D’Silva
JEFFREY LIPTON in BARBADOS – http://feeds.reuters.com/~r/reuters/companyNews/~3/v25Y8XRrUNA/roches-lung-cancer-combo-treatment-wins-fda-approval-idUSL4N1YB65I